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Meta-analysis using individual
participant data: one-stage and two-stage
approaches, and why they may differ
Danielle L. Burke*† Joie Ensor and Richard D. Riley
Meta-analysis using individual participant data (IPD) obtains and synthesises the raw, participant-level data
from a set of relevant studies. The IPD approach is becoming an increasingly popular tool as an alternative to
traditional aggregate data meta-analysis, especially as it avoids reliance on published results and provides an
opportunity to investigate individual-level interactions, such as treatment-effect modiﬁers. There are two
statistical approaches for conducting an IPD meta-analysis: one-stage and two-stage. The one-stage approach
analyses the IPD from all studies simultaneously, for example, in a hierarchical regression model with random
effects. The two-stage approach derives aggregate data (such as effect estimates) in each study separately and
then combines these in a traditional meta-analysis model. There have been numerous comparisons of the
one-stage and two-stage approaches via theoretical consideration, simulation and empirical examples, yet there
remains confusion regarding when each approach should be adopted, and indeed why they may differ.
In this tutorial paper, we outline the key statistical methods for one-stage and two-stage IPD meta-analyses,
and provide 10 key reasons why they may produce different summary results. We explain that most differences
arise because of different modelling assumptions, rather than the choice of one-stage or two-stage itself. We
illustrate the concepts with recently published IPD meta-analyses, summarise key statistical software and
provide recommendations for future IPD meta-analyses. © 2016 The Authors. Statistics in Medicine published
by John Wiley & Sons Ltd.
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1. Introduction
Statistical methods for meta-analysis and evidence synthesis are increasingly popular tools in medical
research, as they synthesise quantitative information across multiple studies to produce evidence-based
results. An aggregate data meta-analysis is the most common approach, where summary study results
(such as treatment effect estimates and their standard errors) are obtained from study publications or
study authors, and then synthesised. This approach is, at least in principle, relatively quick and
inexpensive, but it often faces problems such as poor and selective reporting in primary studies,
publication bias and low power to detect individual-level interactions such as how a participant-level
covariate modiﬁes treatment effect [1,2]. An individual participant data (IPD) meta-analysis can help
overcome many of these issues, by obtaining and then synthesising the raw, participant-level data from
each study. For example, IPD allows the meta-analyst to standardise the inclusion criteria and analyses
across studies, to obtain study results that had not been provided by the trial publications and to check
modelling assumptions [3]. An important advantage is being able to model individual-level interactions
directly within studies, which has substantially greater power and avoids ecological bias compared with
a meta-regression of aggregate data across studies [4,5]. For such reasons, there has been an increase in
the number of IPD meta-analyses in the last decade [5,6].
There are two competing statistical approaches for IPD meta-analysis: a two-stage or a one-stage
approach [7]. In the two-stage approach, ﬁrstly, the IPD from each study are analysed separately in order
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to obtain aggregate (summary) data of interest (such as an effect estimate and its conﬁdence interval
(CI)); then secondly, these are combined by an appropriate ﬁxed-effect or random effects meta-analysis
model. The alternative one-stage IPD meta-analysis approach analyses all the patient-level data from all
the trials in a single step, for example, using a hierarchical (random effects) model that accounts for the
clustering of patients within studies [8]. The two-stage approach is often preferred [2,9] because in
the second stage it uses standard meta-analysis methods that are well documented, for example, in
the Cochrane Handbook [10]. However, one-stage methods have also been recommended because they
use a more exact likelihood speciﬁcation [3,11], which avoids the assumptions of within-study normality
and known within-study variances, which are especially problematic in meta-analyses with small studies
and/or rare events. Yet, one-stage methods are also criticised for being computationally intensive and
prone to convergence problems [3,12].
This discrepant advice is causing a dilemma for researchers who are writing grant applications and
statistical analysis protocols: do they adopt a one-stage or a two-stage approach? This is especially
important as statistical and/or clinical conclusions may depend on the chosen approach. For example,
Debray et al. found that erythema was a statistically signiﬁcant predictor of deep vein thrombosis
(DVT) in a one-stage analysis (p=0.03), but not a two-stage analysis (p=0.12) [3]. For this reason,
Tierney et al. advise, ‘It is important, therefore, that the choice of one or two-stage analysis is speciﬁed
in advance or that results for both approaches are reported’ [13].
To aid this process, this article provides a tutorial of the two-stage and one-stage approaches to IPD
meta-analysis. In Section 2, we introduce the approaches using statistical notation and provide examples
for continuous, binary and time-to-event outcomes, which illustrate how the two approaches often give
similar results. Available statistical software is also summarised. Section 3 then outlines 10 key reasons
why differences may arise to help users resolve them if they occur in practice. In particular, we highlight
that differences are most likely due to the analyst making discrepant modelling assumptions, changing
the speciﬁcation of unknown parameters or using different techniques for model estimation or CI
derivation. Real examples are used to illustrate the messages and include application of ﬁxed-effect
and random effects models for obtaining summary meta-analysis results for treatment and prognostic
effects, treatment-covariate interactions and test accuracy. Section 4 then concludes with some
discussion and recommendations for future IPD meta-analyses.
2. An introduction to one-stage and two-stage IPD meta-analysis models
We now introduce the two approaches using statistical notation, starting with the more familiar
two-stage approach.
2.1. The two-stage approach
2.1.1. First stage. Let us assume that there are i=1 to K trials for the IPD meta-analysis and that a treat-
ment effect is of interest. In the two-stage approach, the ﬁrst stage involves a separate analysis in each
study to derive the K treatment effect estimates and their variances, using an appropriate method chosen
by the meta-analyst. For example, estimates for odds ratios (ORs) or risk ratios (and variances for log
ORs and log relative risks) can be derived using standard formulae [14] after collapsing the IPD to
2×2 contingency tables. More generally, the estimates and standard errors can be derived by ﬁtting a
regression model suitable for the outcome of interest, with a model speciﬁcation deemed appropriate
by the analyst. This enables covariate adjustment if necessary, which is especially important in situations
where confounding is a concern. We focus now on utilising familiar regression models for continuous,
binary and time-to-event outcomes; however, there are many other modelling options available.
If the outcome is continuous (blood pressure, say) then one may use, for example, maximum likeli-
hood (ML) or restricted ML (REML) estimation to ﬁt an appropriate linear regression in each study
separately, such as an analysis of covariance (ANCOVA) model. At baseline (i.e. before randomisation)
the jth participant in the ith trial provides their initial (blood pressure) value, which we denote by yBij
(where B indicates baseline). Also, each participant provides their ﬁnal (blood pressure) value after treat-
ment, which we denote by yFij (where F indicates ﬁnal). Also, let xij be 0/1 for participants in the
control/treatment group, respectively. One can then ﬁt the following ANCOVA model to the IPD in each
trial separately, where the ﬁnal score is regressed against the baseline score and the treatment effect:
yFij ¼ αi þ βi yBij þ θi x ij þ eij (1)
D. L. BURKE, J. ENSOR AND R. D. RILEY
© 2016 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd. Statist. Med. 2016
eijeN 0; σ2i 
In this model, αi is the intercept (the expected response in the placebo group for those with a zero yBij),
θi is the underlying treatment effect (the mean difference in ﬁnal score between treatment groups, after
adjusting for baseline score), βi denotes the mean change in yFij for a one-unit increase in yBij, and σi2 is
the residual variance of the responses after accounting for the treatment effect and the baseline values.
For non-continuous outcomes, generalised linear regression models are usually preferred, such as
binomial logistic regression for binary outcomes, ordinal logistic regression for ordinal outcomes,
multinomial regression for multinomial outcomes and Poisson regression for count outcomes. For
example, for a binary outcome (e.g. death by 1month), one might use ML estimation to ﬁt the
following logistic regression model in each trial separately:
ln
E yij
 
1 E yij
 
0@ 1A ¼ ln pij
1 pij
 !
¼ αi þ θixij (2)
where yij is 1 or 0 for participants with or without the outcome, respectively; pij is the probability of
participant j experiencing the event; αi is the intercept (the expected log odds of the event for the control
group); and θi denotes the treatment effect (the log OR). Baseline covariates might also be included in
equation (2), alongside xij, in order to increase power or to adjust for baseline confounding. If interest
was in relative risks rather than ORs, then one could ﬁt a binomial regression with a log-link or a Poisson
regression with robust standard errors [15].
If the outcome is time-to-event (e.g. time to death), a straightforward approach would be to use ML
estimation to ﬁt a Cox regression model in each study separately,
hij tð Þ ¼ h0i tð Þexp θixij
 
(3)
where hij(t) is the hazard rate over time, t, for participant j; h0i(t) is the baseline hazard (for those in the
placebo group); and θi denotes the log hazard ratio (i.e. the treatment effect). As before, baseline
covariates might also be included in equation (3), alongside xij, in order to increase power or to adjust
for baseline confounding.
Following estimation of an equation such as (1), (2) or (3) in each trial separately, the meta-analyst
obtains K treatment effect estimates, θ ̂i , and their variances, Var( θ î ), ready for the second stage
(see succeeding paragraphs ). If a different measure is of interest, then the equations should be modiﬁed
accordingly to allow the measure to be estimated. For example, to examine the interaction between
baseline value and treatment effect (a so-called ‘treatment–covariate interaction’), equation (1) can be
modiﬁed to
yFij ¼ αi þ βiyBij þ θixij þ λi yBijxij
 
þ eij (4)
eijeN 0; σ2i 
where the interaction term, λi, denotes the mean increase in treatment effect for a one-unit increase in
the baseline value. Estimation of equation (4) in each trial then provides the meta-analyst with
K treatment–covariate interaction estimates (and their variances) ready for the second stage. In the
following subsection, in our description of the second stage, we focus on the synthesis of treatment
effects, but the concepts apply equally to meta-analysis of any parameter estimate of interest.
2.1.2. Second stage. In the second stage, the treatment effect estimates, θ î, obtained in the ﬁrst stage are
then combined across trials, assuming that the true treatment effects are either ﬁxed or random across
studies. The ﬁxed-effect model assumes that θ ̂i are all estimates of the same underlying treatment effect
in all studies, represented as θ. It can be written generally as [16]
θ î eN θ;Varðθ ̂iÞ  (5)
where the Var(θ î) estimates are also taken from the ﬁrst stage, and usually assumed known. The most
common method to estimate θ is the inverse variance method, which provides a weighted average,
where the weight of each trial, wi, is deﬁned as [10]
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wi ¼ 1
var θ î
  (6)
and the pooled treatment effect, θ, and its variance are calculated by
θ ̂ ¼
∑Ki¼1θ îwi
∑Ki¼1wi
(7)
var θ ̂
 
¼ 1
∑Ki¼1wi
(8)
These solutions can also be derived using ML solution estimation. As the ﬁxed-effect model assumes
that the true treatment effect is the same in all studies, the obtained summary estimate, θ ̂, should be
interpreted as the best estimate of this common treatment effect.
The random effects model allows for between-study variation, τ2, in the true treatment effect and
makes the assumption that the different studies are estimating different, yet related, treatment effects.
The random effects model can be written generally as [16]
θ îeN θi;Var θ î   (9)
θieN θ; τ2 
where the Var(θ ̂i) estimates are again assumed known and ui denotes a random-effect, which indicates
that the treatment effect in the ith trial, θi, is assumed normally distributed about an average treatment
effect, θ, with between-study variance, τ2. As the random effects model assumes the true treatment effect
varies across studies, the obtained summary estimate, θ ,̂ should be interpreted as the estimated average
of the distribution of true treatment effects in the meta-analysis. Equation (9) reduces to equation (5)
when τ2 equals zero.
To obtain meta-analysis results, an inverse variance approach can again be taken but with the weights
of each trial now adjusted to incorporate an estimate of τ2:
wi ¼
1
var θ î
 
þ τ ̂2
(10)
Then, the estimate of the pooled effect and its variance are calculated using:
θ ̂ ¼ ∑Ki¼1θ îwi
∑Ki¼1wi
(11)
var θ ̂
 
¼ 1
∑Ki¼1wi
(12)
Perhaps the most popular method of estimating τ2 is the non-iterative, non-parametric methods of
moments (MoM) estimator of DerSimonian and Laird [17], due to its speed and availability in non-
sophisticated statistical packages, such as RevMan [18]. It also avoids the assumption of normally
distributed effects as written in equation (9), as it simply uses the Q-statistic and inverse-variance
weights. Other non-iterative estimators are also available, which have been shown to improve upon
DerSimonian and Laird in some situations [19,20]. Other iterative methods are available to estimate
τ2 and θ in equation (9) [19,21], including ML and REML. Bayesian approaches can also be used,
but these are beyond the scope of this paper. Indeed, there is much ongoing debate in the meta-analysis
literature about the best method to estimate τ2 and (subsequently) θ [22,23], and we return to this issue in
Section 3.
D. L. BURKE, J. ENSOR AND R. D. RILEY
© 2016 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd. Statist. Med. 2016
2.2. The one-stage approach
The one-stage approach analyses all the IPD from all studies simultaneously. The model framework
depends on the outcome type and the model speciﬁcation deemed appropriate by the analyst. In the
succeeding discussion, we again focus on specifying typical models for continuous, binary and time-
to-event outcomes in regard to a summary treatment effect estimate. For survival data, this means we
focus mainly on Cox regression models but recognise that other (ﬂexible) parametric survival model
speciﬁcations are possible. Furthermore, as discussed in the ﬁrst stage of the two-stage approach,
one-stage regression models can also be speciﬁed for alternative outcomes, such as count and ordinal data.
For continuous outcomes, a one-stage IPD meta-analysis can be speciﬁed in a linear (mixed) model.
For example, assuming a ﬁxed treatment effect, the following one-stage ANCOVA model can be ﬁtted
to all studies simultaneously:
yFij ¼ αi þ βiyBij þ θxij þ eij (13)
eijeN 0; σ2i 
The parameters are as deﬁned previously, but we emphasise that the subscript, i, denotes that a
separate parameter is estimated for each study. For example, αi denotes that a separate intercept term
is estimated for each study; this is sometimes referred to as ‘stratifying by trial’, and it allows for differ-
ent mean control group responses per trial and thus accounts for the clustering of participants in trials.
Similarly, βi denotes that each trial has a different adjustment term for baseline values, and σ2i denotes
a distinct residual variance per trial. It is also important to note that the assumptions of distinct baseline
values and residual variances represent just one possible model. Other options are available, and they
will be discussed in this article as possible reasons for differences between the one-stage and two-stage
approaches.
Equation (13) could be extended to include a random treatment effect:
yFij ¼ αi þ βiyBij þ θixij þ eij (14)
θi ¼ θ þ ui
uieN 0; τ2 
eijeN 0; σ2i 
Some researchers also prefer to place a random effect on the study intercepts [24]; for example
equation (13) is then modiﬁed to
yFij ¼ αi þ βiyBij þ θxij þ eij (15)
αieN α; δ2 
eijeN 0; σ2i 
This is potentially a strong assumption, and will usually be unnecessary, but illustrates the so-called
ﬂexibility of the one-stage approach [3]. It is perhaps more realistic and most helpful when the average
baseline response α is also of interest, or when needing to reduce (perhaps due to convergence problems)
the number of parameters to estimate (that is, rather than estimating K intercepts in equation (13), we
now estimate just α and δ in equation (15)). A similar modiﬁcation can be made to equation (14) to
include a random treatment effect and a random study effect, with a suitable correlation structure
between the random effects. Other ‘ﬂexible’modiﬁcations are also possible; for example, assuming each
study has a common (rather than separate) baseline adjustment term and a common (rather than separate)
residual variance [25]. As mentioned, we return to these issues in Section 3. The aforementioned linear
(mixed) models are typically estimated using ML or REML.
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For binary outcomes, a generalised linear (mixed) model is required. For example, a one-stage logistic
regression meta-analysis, with stratiﬁed intercepts and a random treatment effect, can be expressed as
ln
E yij
 
1 E yij
 
0@ 1A ¼ ln pij
1 pij
 !
¼ αi þ θixij (16)
θi ¼ θ þ ui
uieN 0; τ2 
where model parameters are as deﬁned previously. As for the one-stage general linear model, the distinct
intercept term per trial accounts for different baseline (control group) risks and the clustering of partic-
ipants in each trial. Alternative speciﬁcations of equation (16) could be chosen, including a ﬁxed rather
than random treatment effect, and a random rather than stratiﬁed trial-speciﬁc intercept term. Adjustment
terms could also be included, and then the analyst must decide whether a common or distinct adjustment
term is speciﬁed per trial. Estimation is typically performed using ML via a numerical approach such as
Gaussian quadrature.
For time-to-event outcomes, a one-stage Cox regression model can be used [9,12,26,27]. However,
unlike the continuous and binary outcome frameworks, there is the added complexity of whether to
specify unique or proportional baseline hazards for the trials. For example, assuming a random treatment
effect, one might specify proportional baseline hazards by adjusting for a study-speciﬁc effect:
hij tð Þ ¼ h0 tð Þ exp α0i þ θixij
 
(17)
θi ¼ θ þ ui
uieN 0; τ2 
Here, h0(t) is the baseline hazard function in the reference trial (say i=1), and α0i is the proportional
effect on the baseline hazard function due to the ith trial (with α01 constrained to be zero). Alternatively,
we can specify unique baseline hazard functions for each trial (i.e. stratify by trial) by
hij tð Þ ¼ h0i tð Þ exp θixij
 
(18)
θi ¼ θ þ ui
uieN 0; τ2 
where h0i(t) is the unique baseline hazard function in the ith trial. By avoiding the assumption of propor-
tional baseline hazards, equation (18) makes less assumptions than equation (17). As for linear and
logistic models, the ﬂexibility of the one-stage approach also allows the analyst to make other modiﬁca-
tions if desired, including a ﬁxed rather than random treatment effect, a random rather than stratiﬁed
trial-speciﬁc intercept term (for equation (18)) and the inclusion of common adjustment terms.
Estimation of such one-stage Cox models can be via ML or REML [9], which typically avoid estima-
tion of the baseline hazard itself [1,28–30]. Crowther et al. also show how to ﬁt the models in a Poisson
regression framework using ML estimation [26]. If the baseline hazards are themselves of interest (for
example, for developing a prognostic model [31,32]), a one-stage parametric survival model might be
preferred; for example, Crowther et al. use Gauss–Hermite quadrature to estimate a one-stage IPD
meta-analysis model akin to equation (18), but using a ﬂexible parametric approach where the baseline
cumulative hazard is modelled via restricted cubic splines [33].
2.3. Statistical software
Debray et al. provide an excellent overview of statistical software for IPD meta-analysis [1]. They focus
mainly on one-stage models and highlight software that ﬁts the necessary generalised linear mixed
models, such as SAS [34], Stata [35], R [36] and MLwiN [37]. We additionally wish to highlight the
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‘ipdforest’ module in Stata, which produces a forest plot following a one-stage IPD meta-analysis of a
continuous or binary outcome. This gives the one-stage summary result at the bottom of the plot, but
with the study-speciﬁc estimates as derived from the ﬁrst stage of a two-stage analysis [38]. Debray
et al. also do not mention the excellent ‘ipdmetan’ package [39]; a Stata module that automatically
operates the ﬁrst and second stages of the two-stage approach. This can handle any outcome type
(including continuous, binary or time-to-event outcomes) in the ﬁrst stage and offer a wide variety of
estimation options for the second stage, whilst also producing detailed summary results, heterogeneity
statistics and a forest plot. Several modules and software, such as ‘metan’ [40] in Stata, ‘meta’ and
‘metafor’ in R [36,41] and RevMan [18] can perform the ﬁrst stage of a two-stage meta-analysis if
the user provides the 2×2 contingency tables. If users are happy to implement the ﬁrst stage themselves,
then there are also a plethora of other modules and software that can implement the second stage
directly, including ‘metan’ [40], ‘metaan’ [42], ‘metareg’ [43] and ‘mvmeta’ [44] in Stata [45], ‘meta’
and ‘metafor’ in R [36,41], SAS Proc Mixed [46,47] and RevMan [18]. However, the available estima-
tion methods differ considerably across these.
2.4. One-stage and two-stage approaches often give very similar results
Several authors have investigated the difference between one-stage and two-stage IPD meta-analysis
results (for example, see the following [1–3,9,48–50]), either empirically, theoretically or via simulation.
Most authors conclude that they give very similar results. For example, for binary outcomes, Stewart
et al. state,
Major beneﬁts of obtaining IPD are accrued prior to analysis and where an IPD review evaluates
effectiveness based on sufﬁcient data from randomised controlled trials, one-stage statistical anal-
yses may not add much value to simpler two-stage approaches. Researchers should therefore not
be discouraged from undertaking IPD synthesis through lack of advanced statistical support [2].
Debray et al. also investigated any differences in relation to binary outcomes [3] and concluded that
generally, the approaches gives similar results, but all have potential estimation challenges. Also, Senn
(2010) discussed the theoretical equivalence of one-stage and two-stage likelihood speciﬁcations for bi-
nary ﬁxed effects meta-analysis without covariates [51]. Similarly, for time-to-event outcomes, Bowden
et al. conclude that if the aim of a meta-analysis is to estimate the treatment effect under a random effects
model, there appears to be only a very small gain in ﬁtting more complex and computationally intensive
one-stage models [9]. For continuous outcomes, Mathew and Nordstrom (2010) extend previous theo-
retical work to show that one-stage and two-stage summary estimates coincide exactly when ﬁxed treat-
ment and ﬁxed intercept terms are used [52–54].
Two recent overviews of IPD meta-analysis also note that one-stage and two-stage approaches usually
give very similar results [3,13]. To illustrate this, Tierney et al. give a binary outcome example where
the effects of anti-platelets on pre-eclampsia in pregnancy from two-stage (relative risk =0.90, 95%
CI=0.83 to 0.96) and one-stage (relative risk=0.90, 95% CI=0.83 to 0.97) analyses were almost
identical [2,13].
Figure 1(a) gives a continuous outcome example, from a random effects IPD meta-analysis of 10
randomised trials to evaluate the effect of anti-hypertensive treatment on systolic blood pressure [55].
Again, the summary results are almost identical when using either the one-stage (equation (14)) or
two-stage (equation (1) followed by equation (9)) approaches using REML estimation. Figure 1(b) gives
a time-to-event example, showing a ﬁxed-effect IPD meta-analysis of the same 10 hypertension trials
[26]. Again, the summary treatment effect on cardiovascular disease is very similar when using either
a two-stage approach (equation (3) followed by (5)), or a stratiﬁed one-stage approach with a unique
baseline hazard per study (equation (18)), via ML estimation.
3. Key reasons why meta-analysis results may differ for the one-stage and two-stage
approaches
The examples in Section 2.4 echo the wide-spread belief that one-stage and two-stage results are usually
very similar. However, differences can arise [53], and sometimes, these may even be large with discrep-
ant statistical or clinical signiﬁcance [3].
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To aid researchers facing this situation, we now describe 10 key reasons why such differences may
arise even when the same IPD are used for both one-stage and two-stage approaches. These relate to
different modelling assumptions, parameter speciﬁcations and estimation methods. Although some are
Figure 1. One-stage and two-stage IPD meta-analysis summary treatment effect results for (a) mean difference
for ﬁnal systolic blood pressure adjusting for baseline systolic blood pressure and (b) hazard ratio for cardiovas-
cular disease. IPD, individual participant data; CI, conﬁdence interval.
D. L. BURKE, J. ENSOR AND R. D. RILEY
© 2016 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd. Statist. Med. 2016
perhaps obvious, the majority are subtle, and we suspect that most researchers are unaware of their
potential impact. We illustrate each reason with results from previous IPDmeta-analyses. In all examples,
we ensure that exactly the same IPD are used for both one-stage and two-stage analyses, and thus, any
differences cannot be due to discrepant numbers of studies, patients or follow-up times. Some of the
issues are inter-related, but we highlight them separately to make them explicit.
3.1. Reason I: exact one-stage likelihood versus approximate two-stage likelihoods
One-stage and two-stage methods may yield different summary results when the second stage of the
two-stage method assumes that study treatment effect estimates (θ î) have a normal sampling distribution
and that their variances (Var θ ̂i
 
Þ are known [3,11,56,57]. This ﬁrst assumption is based on the central
limit theorem, and the second assumes that the variance is estimated with reasonable accuracy. These
assumptions depend on a combination of the total number of participants in each trial, the number of
participants in each treatment group in each trial and the number of events/non-events in each group
in each trial. Therefore, both assumptions are unlikely to be appropriate for all outcome types when
some or many of the included studies are small (<30 participants). However, if the small trials do not
contribute greatly to the pooled effect (i.e. the weight of these trials is low), then this is a less concerning
issue. The assumptions are more generally unreliable for binary and time-to-event outcomes when
outcomes are rare (or extremely common), as the number of outcomes (and non-outcomes) then drives
the study-speciﬁc estimates and their variances, not just the total participants. In contrast, a one-stage
IPD meta-analysis model, such as a logistic regression model in equation (16), directly models the actual
distribution of the IPD (e.g. binomial for logistic regression) and avoids making any assumptions about the
distribution of the treatment effect estimates in each study. It thereby provides a more exact likelihood spec-
iﬁcation from which to make inferences [11,58]. The one-stage approach may additionally, but perhaps
more critically, be different from the two-stage approach if there are zero event counts for binary outcomes
because the two stage method typically requires a continuity correction (such as +0.5 to cells in the avail-
able two-by-two tables [59–61]), whereas this is not necessary with the one-stage logistic regression model
[11]. The issue that effect estimates are not normally distributed is possibly less of a concern than the issue
of zero cells and subsequent continuity corrections, as the latter actually inﬂuence the magnitude of effect
estimates and their estimated variances, which may introduce bias that then feeds in to the second stage.
We illustrate this issue with an example from Hamza et al. [11] who re-analysed an IPD meta-analysis
of nine studies that assessed the operating characteristics of positron emission tomography in the
diagnosis of Alzheimer’s disease. There were small numbers of patients in each study (range: 19–50)
with a total of 254 diseased patients and 218 true positive test results, and the aim was to summarise
the sensitivity of the positron emission tomography test. Although sensitivity and speciﬁcity are often
analysed together, here, we just consider sensitivity alone; indeed, a joint analysis often makes little dif-
ference anyway [62,63]. However, three studies contained zero false positives (sensitivity =100%), and
therefore, to perform the two-stage approach, Hamza et al. used continuity corrections (+0.5 added to
each cell) in the ﬁrst stage to derive logit-sensitivity estimates and their variances in each study (equation
(2)). In contrast, the one-stage approach does not require such assumptions as it models the binomial
distribution of the IPD directly (here, a logistic regression model with just an intercept term denoting
the logit-sensitivity and an associated random effect). This leads to large differences in the summary
logit-sensitivity estimate between the one-stage (ML estimate: 2.20) and two-stage (ML estimate:
1.71) approaches, relating to a summary sensitivity of 0.90 and 0.85, respectively. The estimated τ2
was also different (0.97 in one-stage analysis, 0.37 in two-stage analysis), which may be especially
important for making predictive inferences about the sensitivity in a new population [64]. Riley et al.
propose how to derive percentage study weights for this example, and these are shown in Figure 2, with
clear differences in the one-stage and two-stage weights (Riley et al., submitted).
3.2. Reason II: likelihood-based one-stage versus alternative weighting schemes in two-stage
As described in Reason I, stage 2 in a two-stage approach is problematic when outcomes are rare and stud-
ies are small and may even be problematic when some studies have unbalanced sample size in the treatment
and control group numbers [10,59,60]. To address this, alternative two-stage approaches have been
proposed, which use a different weighting scheme to the inverse variance method, such as the Peto method
[65] and the Mantel–Haenszel method [66], which also avoid the use of continuity corrections when there
are zero cells. The Peto method is considered to work well when intervention effects are small, event risks
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are <1%, and when there are balanced experimental and control group sizes within trials [10,60]. The
Mantel–Haenszel is often preferred when event risk is>1%, and there are unbalanced data [10].
However, in the context of this article, it is important to emphasise that even these alternative two-
stage methods may give different results to a one-stage meta-analysis that uses the binomial likelihood,
such as a logistic regression. We illustrate this issue with a previous IPD meta-analysis dataset of three
trials that investigated whether erythema is a risk factor for deep vein thrombosis (DVT), as shown in
Debray et al. [3]. In terms of a two-stage approach, the Mantel–Haenszel method might be preferred
in this situation because the event rates are not small (10–29%), and sample sizes are not balanced in
the control and treatment groups in all three trials. Assuming a ﬁxed treatment effect, the summary
results from the Mantel–Haenszel and Peto methods are compared with a one-stage logistic regression
model (equation (16) with a ﬁxed treatment effect) in Table I.
Although summary results are qualitatively similar, the summary OR estimates are slightly lower
for the two-stage methods compared with the one-stage approach. Furthermore, only the one-stage
approach suggests a statistically signiﬁcant increase in the odds of DVT if there is erythema
compared with without. These differences are a consequence of the different weighting schemes
employed by the methods.
3.3. Reason III: clustering and choice of speciﬁcation for the intercept
A two-stage IPD meta-analysis automatically accounts for clustering of patients by trial by analysing the
data from each trial separately in the ﬁrst stage. However, a one-stage IPD meta-analysis models all data
Figure 2. Forest plot of the one-stage and two-stage meta-analysis results for the sensitivity of the PET test for
diagnosis of Alzheimer’s disease. PET, positron emission tomography; IPD, individual participant data; ML,
maximum likelihood.
Table I. Summary results from a ﬁxed-effect IPD meta-analysis of the erythema data using two-stage or one-
stage approaches.
Approach Method Summary OR (95% CI), p-value
Two-stage Mantel–Haenszel 1.277 (0.980 to 1.665), 0.070
Two-stage Peto 1.285 (0.980 to 1.686), 0.069
One-stage Logistic regression 1.352 (1.031 to 1.771), 0.029
IPD, individual participant data; OR, odds ratio; CI, conﬁdence interval.
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simultaneously, and therefore, the analyst must account for the clustering of patients to avoid misleading
effect estimates and conclusions. More speciﬁcally, for logistic regression models, one expects down-
wardly biassed results when ignoring the clustering due to non-collapsibility of the OR [8]. As discussed
in Section 2.2, the clustering can be accounted for by stratifying the analysis by trial (i.e. estimating a
separate intercept or baseline hazard for each trial) or assuming that the intercept (baseline hazard) is
randomly drawn from some distribution. However, there is repeated evidence that some researchers
are ignoring the clustering of patients within trials in the one-stage IPD meta-analyses and are therefore
analysing data as if it were coming from a single study [7,8,67]. This is another key reason why one-
stage and two-stage results may differ.
We illustrate this issue using a previous IPD meta-analysis dataset of two randomised controlled
trials (total patients =1620) that investigated whether nicotine gum increased the odds of smoking
cessation [68]. All parameter estimates are obtained using ML for consistency and assume a ﬁxed treat-
ment effect (Table II). The two-stage approach used equation (2) followed by equation (5), and thus,
the ﬁrst-stage automatically assumed a different intercept term per trial. The one-stage approach that
accounted for clustering used equation (16) with a separate intercept per trial and a ﬁxed treatment
effect; however, the one-stage approach that ignored clustering used the same equation, but with just
a single intercept term.
The results highlight the importance of accounting for clustering. The summary OR estimate and CI
from the one-stage approach ignoring clustering only just suggest that there is a statistically signiﬁcant
association between nicotine gum use and smoking cessation. However, in contrast, the summary OR
estimate from both the two-stage and one-stage approaches that account for clustering are substantially
higher, and there is much stronger statistical evidence that nicotine gum is beneﬁcial.
Thus, clustering must be accounted for; yet, even the choice of how the clustering is accounted for
may cause differences. For example, for continuous outcomes, Matthew and Nordstrom (2010) suggest
that a one-stage approach with a random intercept term may be slightly more precise than a two-stage
IPD meta-analysis (which has a distinct intercept term per study) [53]. For time-to-event outcomes, there
are even more options. In a two-stage IPD meta-analysis, the baseline hazard is uniquely estimated in
each trial separately, and thus, there is no assumption about how the shape or magnitude of the baseline
hazard is related across trials. In a one-stage meta-analysis, the analyst could also assume this (equation
(18)) but, due to the greater ﬂexibility of the approach, could alternatively assume that the baseline haz-
ards are distinct but proportional to each other (as in equation (17)) or assume a random effect (frailty)
for the baseline hazard; for example, the ‘shared’ option within the ‘stcox’ module within Stata treats the
frailties as being gamma distributed (mainly for computational convenience) [35]. In our experience, this
decision usually only leads to small differences in the summary treatment effect. For example, in an IPD
meta-analysis of 1225 patients from ﬁve clinical trials in epilepsy that investigated the effect of treatment
on time to remission [29], a one-stage IPD meta-analysis Cox model with proportional baseline hazards
(equation (17)) gave a summary hazard ratio of 0.89 (95% CI: 0.77 to 1.03, p=0.115). The summary
hazard ratio was 0.90 (95% CI: 0.78 to 1.03, p=0.130) in a Cox model with unique baseline hazard
functions for each trial, and 0.90 (95% CI: 0.78 to 1.04, p=0.153) assuming a frailty model. The differ-
ences are qualitatively small; nevertheless, changes in the p-value are still apparent and may be more
pertinent in other examples.
3.4. Reason IV: choice of speciﬁcation for any adjustment terms
Similar to the choice of intercept (baseline hazard) speciﬁcation, in a one-stage IPD meta-analysis, the
analyst can also adopt different speciﬁcations for any adjustment terms (such as adjustment for baseline
score in an ANCOVA, equation (13)). A two-stage approach automatically assumes a different effect of
each adjustment factor in each trial, as it analyses each trial separately in the ﬁrst stage (equation (1)). A
Table II. Fixed-effect one-stage and two-stage approaches to illustrate the effect of clustering in the nicotine
gum dataset [68].
Approach Clustering Summary OR (95% CI OR)
Two-stage Accounting for clustering 1.769 (1.257 to 2.488)
One-stage Ignoring clustering 1.398 (1.020 to 1.916)
One-stage Accounting for clustering 1.802 (1.290 to 2.517)
OR, odds ratio; CI, conﬁdence interval; τ2, between-study heterogeneity.
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one-stage approach can replicate this by stratifying the effect by study (as in equation (13)), but alterna-
tively, the analyst could assume that the effects were random or even ﬁxed. The ﬁxed assumption is
likely an over-simpliﬁcation, but our experience suggests that it is often adopted in practice, perhaps
unknowingly.
The choice of speciﬁcation of adjustment factors may lead to differences between the one-stage and
two-stage approaches, particularly if the effect of the adjustment factor is heterogeneous across the trials.
When there are multiple random effects, the speciﬁcation of their covariance matrix (e.g. unstructured or
independent) may also be inﬂuential.
We illustrate this using an IPD meta-analysis by Riley et al. [55], which used the 10 hypertension
trials introduced in Section 2.4. Here, instead of focussing on the treatment effect, the objective was
to examine whether smoking is a prognostic factor for high systolic blood pressure at follow-up, after
adjusting for baseline blood pressure and treatment group. Utilising a one-stage linear regression model
(similar to equation (14) with an additional term for smoking), we compare REML results for the
smoking effect when including baseline blood pressure and treatment group as (a) ﬁxed, (b) random with
an unstructured covariance structure, (c) random with an independent covariance structure or (d) distinct
adjustment terms for each trial. All models assumed a random effect for smoking. The competing two-
stage approach used a linear regression model (similar to equation (1) with additional term for smoking
and parameters estimated) in each trial separately with smoking status, baseline blood pressure and treat-
ment group, and then a random effects meta-analysis model (equation (9)) using REML to synthesise the
smoking effect in the second stage.
Table III shows that the estimate and 95% CI of the summary effect of smoking differs depending on
how the adjustment terms were accounted for, although all approaches suggest smoking is a prognostic
factor. The one-stage approach with distinct adjustment terms is very similar to the two-stage approach,
as expected as the two-stage approach also makes the same assumption. However, the one-stage
approach with ﬁxed or random adjustment terms (especially with an unstructured covariance matrix)
gives a lower prognostic effect and a wider CI.
3.5. Reason V: choice of speciﬁcation for the residual variances
For continuous outcomes, in the two-stage approach, the residual variances are automatically distinct in
each trial, as separate linear models are applied to each trial (equation (1)). In a one-stage IPD meta-
analysis, such as in equation (14), the residual variance can also be allowed to vary by trial, such that
eij~N(0, σi2). However, it is possible to simplify this and make an additional assumption that all trials
have the same residual variance, such that eij~N(0, σ2). In our experience, many one-stage analysts
are not aware that they even make this assumption, but it can cause summary results to differ to those
from the two-stage approach. This is illustrated using the IPD meta-analysis of hypertension trials again
(introduced in Section 2.4).
When we assume different residual variances for each trial, the one-stage and two-stage results are
almost identical (Table IV). However, the one-stage analysis that assumes the same residual variance
in each trial gives a slightly larger summary result, a larger estimate of τ2 and wider CIs. The larger
τ ̂2 is caused by the mis-speciﬁed residual variances. Although clinical conclusions are qualitatively
the same, this illustrates how the speciﬁcation of the residual variances can potentially cause differences
in meta-analysis estimates. For multivariate responses (e.g. multiple time points), a related issue is
Table III. One-stage and two-stage REML results for the effect of smoking on blood pressure at follow-up
after different speciﬁcations of the adjustment for baseline blood pressure and treatment group.
Approach Model speciﬁcation in regard
to adjustment factors
Summary mean difference (smokers versus
non-smokers), 95% CI
τ ̂2
Two-stage Distinct per trial 1.763 (1.146 to 2.380) 0.227
One-stage Fixed 1.689 (0.951 to 2.426) 0.271
One-stage Random (correlated*) 1.523 (0.731 to 2.316) 0.510
One-stage Random (independent*) 1.744 (1.027 to 2.461) 0.235
One-stage Distinct per trial 1.756 (1.043 to 2.469) 0.229
*Unstructured or independent covariance structure for all included random-effects.
REML, restricted maximum likelihood; CI, conﬁdence interval; τ2, between-study heterogeneity in the smoking effect.
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whether the analyses allow for separate or common residual variances for each endpoint, or separate or
common correlations between endpoints (Reason IX).
3.6. Reason VI: choice of ﬁxed-effect or random effects for the parameter of interest
Perhaps the most obvious explanation for any differences in one-stage or two-stage approaches is that,
for the parameter of interest, the meta-analyst may be assuming a ﬁxed-effect in one approach and
random effects in the other. For example, using the hypertension dataset again, we ﬁtted an ANCOVA
model to evaluate the effect of hypertension treatment on blood pressure, with a ﬁxed treatment effect in
a one-stage approach (equation (13)), and a random treatment effect in a two-stage approach (equation
(1) followed by equation (9)). The summary treatment effect in the one-stage approach was 9.31 (95%
CI: 9.70 to8.92) compared with10.17 (95% CI:11.99 to 8.35) in the two-stage approach, with
the lower effect in the one-stage approach due to the ﬁxed-effect assumption. Sometimes, a ﬁxed-effect
assumption may be enforced when using the one-stage approach, due to convergence problems
(especially when the outcome is rare [3]) or computational time (especially for time-to-event outcomes
with large datasets [12]), thus preventing a direct comparison with a two-stage random effects analysis.
3.7. Reason VII: different estimation method for τ2
There are various estimation methods for the between-study heterogeneity parameter, τ2, as mentioned
in Section 2. However, some are only available in a two-stage approach and others in only the one-stage
approach. Furthermore, some estimation methods may fail to converge because of small numbers of
studies in the meta-analysis or large within-study variances [3]. Therefore, differences in one-stage
and two-stage meta-analysis results may be a consequence of different estimation methods. For example,
it is well known that the ML method tends to underestimate the between-study heterogeneity [69–74]
and that REML is preferred in comparison. However, for non-continuous outcomes, one-stage models
typically use ML estimation as it is usually the only option. Furthermore, the MoM estimator of
DerSimonian and Laird is still the most common estimation method applied in the two-stage approach
and is the only option available in RevMan, for example.
We now compare the IPD meta-analysis results for the 10 hypertension trials once more, according to
different estimation methods. For the two-stage approach, we ﬁtted model (1) and then adopted a
random effects model (9), which was estimated using either MoM, ML or REML. In a one-stage model,
ANCOVA model (14) was ﬁtted, and the model parameters are estimated using REML or ML. The
results are shown in Table V.
Table V. Summary treatment effect results for the hypertension data to illustrate the differences in summary
results according to the estimation method.
Approach Estimation method Summary mean difference (95% CI) τ ̂2
Two-stage MoM 9.85 (11.13 to 8.57) 3.07
Two-stage ML 10.10 (12.03 to 8.16) 5.84
Two-stage REML 10.17 (12.27 to 8.07) 7.10
One-stage ML 10.03 (11.83 to 8.23) 4.94
One-stage REML 10.16 (12.27 to 8.06) 7.13
CI, conﬁdence interval; MoM, method-of-moments; ML, maximum likelihood; REML, restricted maximum likeli-
hood; τ2, between-study heterogeneity in the treatment effect.
Table IV. One-stage and two-stage REML results for the effect of hypertension treatment on systolic blood
pressure, after different speciﬁcations of the residual variances.
Approach Assumption of residual
variances in the trials
Summary mean difference
(95% CI)
τ ̂2
One-stage Same in each trial 10.34 (12.55 to 8.13) 8.19
One-stage Distinct per trial 10.16 (12.27 to 8.06) 7.13
Two-stage Distinct per trial 10.17 (12.27 to 8.07) 7.10
REML, restricted maximum likelihood; CI, conﬁdence interval; τ2, between-study heterogeneity in the treatment
effect.
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Although summary treatment effect estimates are broadly similar regardless of the estimation
approach, it is notable that the estimate of the between-study variance is substantially affected. For
example, τ ̂2 is much smaller with the MoM estimator in a two-stage approach (τ ̂2 = 3.07) compared with
the estimate from a one-stage approach via REML (τ ̂2 = 7.13). Larger τ ̂2 estimates lead to wider 95% CIs
for the summary treatment effect and would have even more impact upon predictive inferences, such as
95% prediction intervals [75]. If the same estimation method is used for a one-stage or two-stage
approach, the summary estimates and 95% CI are very similar. The choice of best estimator for τ ̂2 is
an ongoing issue in the meta-analysis ﬁeld [21].
3.8. Reason VIII: derivation of CIs
Not only are there competing estimation methods for ﬁtting the random effects meta-analysis model, but
there are also competing methods for the derivation of 95% CIs for the summary effect post-estimation.
Standard CIs based on the normal distribution (calculated using the summary estimate ±1.96× s.e. of the
summary estimate) are often too narrow, especially because τ ̂2 is often underestimated and no account is
taken of the additional uncertainty in τ ̂2 [22,76]. Therefore, alternative methods have been proposed for
deriving 95% CIs in the two-stage approach, such as the Hartung–Knapp–Sidik-Jonkman (HKSJ) mod-
iﬁcation to the variance of the summary estimate [77–81], combined with the t-distribution with k1
(k=number of studies) degrees of freedom (rather than 1.96 from the standard normal distribution). In
a one-stage approach, the standard approach is again to use the normal distribution from which large
sample inferences are based. However, there are also various methods for small-sample inference based
on the t-distribution, also known as denominator-degrees-of-freedom adjustments, including
Satterthwaite and Kenward-Roger [82].
Therefore, differences in 95% CIs from one-stage and two-stage approaches may simply be due to the
different derivation methods embedded in software packages (e.g. the standard approach is the default in
the Stata package ‘metan’ [40], but the HKSJ is the default in the Stata package ‘metareg’ [43]). To
illustrate this, we return again to the hypertension example. Figure 1 already showed how standard
CIs for the summary treatment effect were almost identical for one-stage and two-stage analyses
(12.27 to 8.07). However, the 95% CI is slightly wider (12.44 to 7.90) in a two-stage approach
using the HKSJ variance estimator and t-distribution.
3.9. Reason IX: accounting for correlation amongst parameters
A one-stage approach automatically accounts for all correlation amongst included parameters during
model estimation. However, a standard two-stage approach (as outlined in Section 2) does not account
for such correlations unless a multivariate meta-analysis model is used to jointly synthesise all parame-
ters, whilst accounting for their within-study, and possibly between-study, correlations [55,83]. This
could lead to the standard two-stage approach having reduced efﬁciency and even a change in the
summary estimates. Sometimes, even if desired, the multivariate model may not be estimable, especially
when there are many parameters to jointly synthesise, because of the lack of information to estimate the
between-study variance–covariance matrix (particularly the unstructured option).
Consider a meta-analysis of longitudinal outcomes, where each patient in a trial provides an outcome
value at each of multiple time points during follow-up. These patients responses, and indeed subsequent
parameter estimates (such as treatment effects at multiple time points), will be correlated, and ignoring
this in the meta-analysis is inadvisable [84,85]. Usually, there are missing data in such situations, such
that not all patients provide all time points; furthermore, not all studies will measure the same time
points. In a one-stage analysis of all time points, under a missing at random assumption, even patients
and studies with missing time points will still contribute towards the estimation of parameters at all time
points, by utilising the correlation amongst them. However, a standard univariate two-stage analysis will
typically take each time point separately, and thus exclude patients or studies at particular time points if
they did not provide data.
An example of this was illustrated by Jones et al. using an IPD meta-analysis of longitudinal data
from ﬁve trials that investigated Selegiline versus placebo for the treatment of Alzheimer’s disease
[84,86]. The outcome of interest over time was the mini-mental state examination, which is a measure
of cognitive function. Patients were repeatedly followed up over time at 1, 2, 4, 6, and 12months;
however, the set of time points available in each trial was different, and not all patients provided all time
points in the same trial. The one-stage approach applied a linear regression model including a separate
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intercept, baseline adjustment term, and residual variance for each trial, and a ﬁxed treatment effect as-
sumed at each distinct time point. This approach accounts for the correlation amongst patient responses
with correlated residuals, and handles missing time point data for participants and trials via a missing at
random assumption. The two-stage approach ﬁrstly analysed each trial separately accounting for corre-
lated patient responses within each trial, to produce a treatment effect at each time point reported; how-
ever, in the second stage, each time point was analysed separately (independently), ignoring correlation
amongst time points, and thus studies only contributed towards the time points they reported.
There are large differences in the summary treatment effects and their standard errors for the two-stage
and one-stage approaches (Table VI). For example, at time point 4months, the treatment effect is 0.34
(s.e. = 0.48) for the one-stage model, compared with 0.75 (s.e. = 0.57) for the two-stage model. Differ-
ences are due to the one-stage approach utilising the correlation amongst time points, which allows
the ‘borrowing of strength’ from the available data to inform the missing data and increases precision
[87]. When a multivariate model is used in the second stage of the two-stage approach to account for
the correlation, the results become almost identical to those from the one-stage method [84].
3.10. Reason X: ecological bias for treatment covariate interactions
When one wishes to model treatment–covariate interactions, it is important to avoid ecological bias,
which occurs when across-study associations (between mean covariate values and treatment effects
across trials) do not reﬂect the true within-study relationships (between individual covariate values
and individual response to treatment) [4,88]. For example, when looking at the interaction between
sex and treatment effect, across-study associations would allow studies with only males (or only
females) to be included, despite containing no within-study differences between males and females.
We note that a similar problem would occur if one used data from single arm trials in a meta-analysis
to inform the estimate of overall treatment effect [51].
A two-stage approach to the estimation of treatment–covariate interactions automatically avoids
ecological bias by ﬁtting a separate model (such as equation (4)) in each trial to obtain within-study
interaction estimates, which are then synthesised in the second stage. Thus any across-study associa-
tions are ignored. This can be replicated in a one-stage approach by separating the within-study and
across-study interaction effects to avoid ecological bias; this is achieved by centring the patient-level
covariate about its mean [88–90] (refer to Appendix section). If the within-study and across-study in-
teraction effects are not separated in the model, then the resulting interaction effect is an amalgamation
of the within-study and the across-study associations, which does not necessarily reﬂect the patient-
level interaction and may lead to misleading conclusions [89]. Unfortunately, this issue is not well
Table VI. ML results of one-stage and two-stage meta-analysis of MMSE longitudinal data: estimates
(standard error) of difference between Selegiline and Placebo.
Time point One-stage
model
Standard two-stage approach (each
time point assumed independent)
Multivariate two-stage approach (correlation
amongst time points accounted for)
1month 0.31 (0.47) 0.43 (0.54) 0.30 (0.47)
2months 0.48 (0.62) 0.84 (0.97) 0.47 (0.59)
4months 0.34 (0.48) 0.75 (0.57) 0.33 (0.47)
6months 0.20 (0.49) 0.31 (0.50) 0.19 (0.48)
9months 0.35 (0.53) 0.69 (0.63) 0.34 (0.52)
12months 0.02 (0.56) 0.29 (0.66) 0.03 (0.55)
ML, maximum likelihood; MMSE, mini-mental state examination.
Table VII. One-stage and two-stage IPD meta-analysis results for treatment–age interactions in the hyperten-
sion dataset according to within-trial, across-trial and amalgamated interactions.
Interaction
covariate
One-stage Two-stage
Amalgamated interaction
(95% CI), p-value
Within-trial interaction
(95% CI), p-value
Across-trial interaction
(95% CI), p-value
Within-trial interaction
(95% CI), p-value
Age 0.067 (0.094 to
0.040), <0.001
0.050 (0.116 to
0.017), 0.142
0.071 (0.100 to
0.041), <0.001
0.049 (0.115 to
0.017), 0.142
IPD, individual participant data; CI, conﬁdence interval.
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recognised, and in our experience, most researchers unknowingly ﬁt the amalgamated interaction term
in their one-stage models.
The approaches are illustrated by the hypertension dataset again where the outcome is blood pressure
and the summary parameter of interest is the patient-level interaction of treatment effect with age. Riley
et al. ﬁtted one-stage ANCOVA models that either amalgamated the interactions or separated them out
[89]. In the two-stage approach, equation (1) was ﬁtted with age and an interaction with age and
treatment. A ﬁxed interaction term was assumed for both one-stage and two-stage models, and results
obtained using REML are shown in Table VII.
The one-stage approach with the amalgamated interaction estimate suggests a statistically signiﬁcant
association between age and treatment effect (95% CI: 0.094 to 0.040). However, when the one-
stage analysis correctly separates the within-trial and across-trial interactions, the summary within-trial
interaction is no longer statistically signiﬁcant (95% CI: 0.116 to 0.017), and gives results almost iden-
tical to the two-stage approach. Therefore, the speciﬁcation of within-trial and across-trial interactions in
a one-stage analysis can lead to differences with the two-stage approach and can inﬂuence statistical and
clinical conclusions.
4. Discussion
We have outlined the key framework for one-stage and two-stage IPD meta-analysis models. Previous
authors have compared one-stage and two-stage approaches through theoretical consideration [52–54],
simulation [9,49] and empirical examples [2,9,48,49], and found that largely the two approaches
produce similar results. Although we agree that this will generally be the case, Section 3 described 10
reasons why one-stage and two-stage results may differ to help the user to understand why differences
may arise in their own IPD meta-analyses and illustrated these using a range of examples, including both
ﬁxed-effect and random effects models. Although in some examples the differences were small or
qualitatively unimportant, in others, the clinical and/or statistical conclusions were affected.
Most differences between one-stage and two-stage approaches occur because of different modelling
assumptions, including the speciﬁcation of the likelihood and included parameters, the choice of ﬁxed
or random effects and the utilisation of correlation. Choosing a different estimation procedure may also
lead to important differences, especially in the random effects setting. Another way of understanding this
is that the different assumptions, parameter speciﬁcations and estimation methods lead to different
percentage study weights in the one-stage and a two-stage meta-analysis (Riley et al. submitted), and
therefore, summary results can differ because of a change in weighting. However, when the same
assumptions are made in both approaches (and these assumptions are plausible), and the same estimation
method is used, the resulting estimates should be very similar, which was demonstrated by the hyperten-
sion data example in Section 2.4.
We note, quite importantly, that whilst the one-stage versus two-stage issue is mainly of concern in
IPD meta-analysis, one-stage analyses are sometimes possible with published data, and the same simi-
larities and differences apply. For example, for binary outcomes, the analyst can essentially reconstruct
the IPD if they extract 2×2 contingency tables from each trial report and then proceed to perform one-
stage logistic regression analyses [91] (such as equation (16)), as long as no adjustment for covariates is
required.
We focused on summary results and their 95% CIs throughout the article. However, we recognise that
other measures may also be of interest such as 95% prediction intervals [92], for which differences may
be even more pronounced. We also acknowledge that, although in our experience our 10 reasons are the
most likely, the list is not exhaustive, and it may be possible to get differences for other reasons. For ex-
ample, the meta-analyst may include covariate adjustment for all studies in a one-stage approach, but in
the two-stage approach may only include covariate adjustment for a subset of trials. The issue of missing
data has also not been explicitly addressed in this paper. In particular, we did not consider differences in
one-stage and two-stage results after the imputation of missing participant data, although recognising
this is a growing area of interest [1,93–98]. However, in our longitudinal example, we noted that missing
outcome data is handled naturally in the one-stage approach under a missing at random assumption,
which allows more efﬁcient results by accounting for correlation between time points. Another issue
not previously mentioned is how automated selection procedures may lead to differences in one-stage
and two-stage results, for example, in regard to identifying the best ﬁtting (non-linear) trend for a con-
tinuous predictor in a prognostic model [99]. Abo-Zaid gives an example where the one-stage approach
suggests a quadratic trend between age and log-odds of death, whereas the two-stage approach suggests
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that a linear trend is preferred in each study and so a pooled linear trend is then obtained [100]. By con-
sidering the trends in each study separately, the two-stage approach had lower power than the one-stage
approach to identify (at a pre-deﬁned signiﬁcance level) more complex relationships. However, if a
quadratic trend had been forced in each study and then combined, the pooled quadratic trend would have
been very similar to that from the one-stage analysis.
So, should researchers choose a one-stage or a two-stage approach? We do not believe there is a
‘blanket’ answer to this question as it depends on many factors, including the clinical question, the
parameter(s) of interest, the desired speciﬁcation of the model, the desired estimation method, the
assumptions willing to be made, the potential for non-convergence and missing data, and the likelihood
of small study sizes and rare events. However, we make some speciﬁc recommendations in Box 1. In
particular, we agree with Debray et al. that ‘when planning an IPD meta-analysis, the choice and imple-
mentation of a one-stage or two-stage method should be pre-speciﬁed in the protocol as occasionally
they lead to different conclusions’ [3]. Moreover, the exact speciﬁcation of the models should also be
pre-speciﬁed where possible, for example, in regard to the choice of ﬁxed or random effects, the
handling of adjustment factors, how clustering within studies will be accounted for, whether ecological
bias will be removed, and (for time-to-event outcomes) the speciﬁcation of the baseline hazards. Once
the analyst has considered the assumptions they want to make and decided that they are plausible in
either a one-stage or two-stage framework, then they could adopt either method as they are likely to give
very similar results. However, in some situations, the assumptions may be more plausible in the one-
stage approach. In particular, for situations of rare outcomes and/or small studies, the one-stage approach
is our preferred option, in order to use a more exact likelihood, and to avoid making assumptions about
within-study normality and known within-study variances. However, even in this situation, the one-
stage approach may suffer from convergence issues, which are difﬁcult to identify in advance. Further-
more, estimation options such as REML may only be available in a two-stage approach, which may help
reduce downward bias in estimates of between-study variances in one-stage ML models.
For such reasons, or if the best choice of model speciﬁcation and/or estimation method are unclear, a
sensible strategy is to pre-specify that both one-stage and two-stage analyses will be undertaken, and
their results compared with check whether conclusions are the same. If they differ, then the meta-analyst
should seek to understand why, and the 10 reasons outlined should help elicit the explanation.
Box 1: Key recommendations for the adoption of one-stage or two-stage IPD meta-analyses.
• State prior to analysis whether a one-stage or two-stage approach will be used for an IPD
meta-analysis. If the best choice is unclear, or if estimation difﬁculties are a concern (e.g. due
to rare outcomes), then it is sensible to state that both approaches will be undertaken, and results
compared.
• Where both one-stage and two-stage approaches are undertaken, both should be reported in
subsequent publications for transparency, and any important differences between them should
be explained.
• The estimation method(s) should be speciﬁed in advance for both one-stage and two-stage
approaches, as the choice can inﬂuence the ﬁndings and the magnitude of differences between
the approaches.
• The model assumptions (e.g. likelihood speciﬁcation, choice of ﬁxed or random effects) and
parameter speciﬁcations (e.g. handling of adjustment factors and baseline hazards in each trial)
should be pre-speciﬁed regardless of whether one-stage or two-stage approaches are used.
• For all outcome types where studies are expected to be small, and in particular, for binary and
time-to-event outcomes that are rare (or extremely common), then a one-stage approach is
preferred, as it avoids the use of approximate normal sampling distributions, known
within-study variances, and continuity corrections that plague the two-stage approach with an
inverse variance weighting.
• Any one-stage analysis should account for the clustering of participants with studies. This is
best achieved by including a separate intercept (distinct baseline hazard) per trial. One could
(if considered plausible) also assume trial intercepts are drawn from some distribution or, for
time-to-event outcomes, assume baseline hazards are proportional across trials, but this will
usually be unnecessary unless interest lies in the intercept or baseline hazard itself (e.g. for
developing a prognostic model).
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• In a one-stage approach, it is best to include separate adjustment terms (when included) and
separate residual variance terms (for continuous outcomes) for each trial, as this makes less
assumptions than a model with common adjustment terms and residual variances. Only when
estimation issues arise might it be necessary to move away from this, for which random effects
on adjustment terms may be helpful.
• Where random effects models are used, consider methods to derive 95% CIs for the summary
effect that account for full uncertainty in the estimated variances in the meta-analysis. For
example, for the two-stage approach, the use of methods such as the HKSJ variance estimator
and t-distribution to estimate CIs might be considered, and for the one-stage approach, the use
of Kenward–Roger variance estimator and t-distribution may be useful.
• A standard two-stage approach does not automatically account for correlation between the
parameters of the regression model estimated in the ﬁrst stage; this may lead to loss in precision
and different summary estimates than the one-stage approach, which automatically accounts for
such correlation. This is especially important if there are missing outcome data, for example,
missing outcomes at some time points in a meta-analysis of longitudinal data. To account for
correlation in a two-stage meta-analysis, a multivariate model is required in the second stage.
• In a one-stage IPD meta-analysis, treatment–covariate interactions should be separated into
within-trial and across-trial interactions to avoid ecological bias. This is automatically avoided
in a two-stage analysis when within-study interaction estimates are obtained in each trial and
then synthesised.
Appendix: Treatment–covariate interactions in a one-stage IPD meta-analysis
A one-stage approach must ﬁt a model that separates the within-study and across-study interaction ef-
fects to avoid ecological bias. The one-stage ANCOVA model (equation (14)) can be extended such that
Y ij ¼ αj þ βiyBij þ θjtreatij þ βjzij þ γW treatij* zij  zj
 þ εij
θj ¼ αþ γAzj þ uj
εijeN 0; σ2j 
ujeN 0; τ2 
Here, zij denotes the covariate of interest, the ﬁxed-effect within-study interaction effect is denoted by
γW and the across trials interaction is denoted by γA (which is also the meta-regression result). The
unexplained between-study variance of the treatment effect is given by τ2, and the covariate is centred
about the mean covariate value, zi in each study to ensure that the within-study interaction is separated
from the across-study interaction. If the within-study and across-study interaction effects are not
separated in the model, then the resulting interaction effect is an amalgamation of the two different
interaction effects [89].
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